Effect of Bacille Calmette–Guérin vaccination on immune responses to SARS-CoV-2 and COVID-19 vaccination

NL Messina; S Germano; AW Chung; CE van de Sandt; NE Stevens; LF Allen; R Bonnici; J Croda; C Counoupas; B Grubor-Bauk; ER Haycroft; K Kedzierska; E McDonald; R McElroy; MG Netea; B Novakovic; KP Perrett; LF Pittet; RA Purcell; K Subbarao; JA Triccas; DJ Lynn; N Curtis; A Davidson; K Gardiner; A Gwee; T Jamieson; T Morawakage; S Perlen; K Perrett; A Sastry; JW Teo; F Orsini; K Lee; C Moore; S Vidmar; R Ali; R Dunn; P Edler; G Gell; C Goodall; R Hall; A Krastev; N La; N McPhate; T Nguyen; J Ren; L Stevens; A Alamrousi; T Dang; J Hua; M Razmovska; S Reddiex; X Wang; J Anderson; K Azzopardi; V Bennett-Wood; A Czajko; N Mazarakis; C McCafferty; F Oppedisano; B Ortika; C Pell; L Spry; R Toh; S Velagapudi; A Vlahos; A Wee-Hee; P Ramos; K De La Cruz; D Gamage; A Karunanayake; I Mezzetti; B Ong; R Singh; E Sooriyarachchi; S Nicholson; N Cain; R Brizuela; H Huang; V Abruzzo; M Bealing; P Bimboese; K Bowes; E Burrell; J Chan; J Cushnahan; H Elborough; O Elkington; K Fahey; M Fernandez; C Flynn; S Fowler; MG Andrit

Journal article

Effect of Bacille Calmette–Guérin vaccination on immune responses to SARS-CoV-2 and COVID-19 vaccination

NL Messina, S Germano, AW Chung, CE van de Sandt, NE Stevens, LF Allen, R Bonnici, J Croda, C Counoupas, B Grubor-Bauk, ER Haycroft, K Kedzierska, E McDonald, R McElroy, MG Netea, B Novakovic, KP Perrett, LF Pittet, RA Purcell, K Subbarao Show all

Clinical and Translational Immunology | Wiley | Published : 2025

DOI: 10.1002/cti2.70023

Download PDF

Abstract

Objectives: Bacille Calmette–Guérin (BCG) vaccination has off-target effects on disease risk for unrelated infections and immune responses to vaccines. This study aimed to determine the immunomodulatory effects of BCG vaccination on immune responses to vaccines against SARS-CoV-2. Methods: Blood samples, from a subset of 275 SARS-CoV-2-naïve healthcare workers randomised to BCG vaccination (BCG group) or no BCG vaccination (Control group) in the BRACE trial, were collected before and 28 days after the primary course (two doses) of ChAdOx1-S (Oxford-AstraZeneca) or BNT162b2 (Pfizer-BioNTech) vaccination. SARS-CoV-2-specific antibodies were measured using ELISA and multiplex bead array, whole ..

View full abstract